Scholars@Duke

Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias

Publication ,  Journal Article
Fabbro, SK; Smith, SM; Dubovsky, JA; Gru, AA; Jones, JA
Published in: JAMA Oncology
August 1, 2015
Published version (DOI) Publisher Link

Duke Scholars

Sabrina Michelle Shearer
Author Sabrina Michelle Shearer Dermatology
Altmetric Attention Stats
Dimensions Citation Stats

Published In

JAMA Oncology

DOI

10.1001/jamaoncol.2015.0457

ISSN

2374-2437

Publication Date

August 1, 2015

Volume

1

Issue

5

Start / End Page

684 / 684

Publisher

American Medical Association (AMA)

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1117 Public Health and Health Services
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fabbro, S. K., Smith, S. M., Dubovsky, J. A., Gru, A. A., & Jones, J. A. (2015). Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias. JAMA Oncology, 1(5), 684–684. https://doi.org/10.1001/jamaoncol.2015.0457
Fabbro, Stephanie K., Sabrina M. Smith, Jason A. Dubovsky, Alejandro A. Gru, and Jeffrey A. Jones. “Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias.” JAMA Oncology 1, no. 5 (August 1, 2015): 684–684. https://doi.org/10.1001/jamaoncol.2015.0457.
Fabbro SK, Smith SM, Dubovsky JA, Gru AA, Jones JA. Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias. JAMA Oncology. 2015 Aug 1;1(5):684–684.
Fabbro, Stephanie K., et al. “Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias.” JAMA Oncology, vol. 1, no. 5, American Medical Association (AMA), Aug. 2015, pp. 684–684. Crossref, doi:10.1001/jamaoncol.2015.0457.
Fabbro SK, Smith SM, Dubovsky JA, Gru AA, Jones JA. Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias. JAMA Oncology. American Medical Association (AMA); 2015 Aug 1;1(5):684–684.

Published In

JAMA Oncology

DOI

10.1001/jamaoncol.2015.0457

ISSN

2374-2437

Publication Date

August 1, 2015

Volume

1

Issue

5

Start / End Page

684 / 684

Publisher

American Medical Association (AMA)

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1117 Public Health and Health Services
  • 1112 Oncology and Carcinogenesis